|
Cognition Disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Together, these data suggest that AIE-induced adult neuroimmune signaling and cognitive deficits are linked to suppression of Chat and Trka gene expression through epigenetic mechanisms that can be restored by exercise.
|
30779268 |
2020 |
|
Nephrosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to show the superiority of TRK-100STP over placebos in patients with chronic kidney disease (with either primary glomerular disease or nephrosclerosis) to determine the recommended dose.
|
31119846 |
2020 |
|
Renal fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of tyrosine kinase receptor signaling attenuates fibrogenesis in an <i>ex vivo</i> model of human renal fibrosis.
|
31736352 |
2020 |
|
Renal glomerular disease
|
0.010 |
Biomarker
|
group |
BEFREE |
This study aimed to show the superiority of TRK-100STP over placebos in patients with chronic kidney disease (with either primary glomerular disease or nephrosclerosis) to determine the recommended dose.
|
31119846 |
2020 |
|
Impaired cognition
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Together, these data suggest that AIE-induced adult neuroimmune signaling and cognitive deficits are linked to suppression of Chat and Trka gene expression through epigenetic mechanisms that can be restored by exercise.
|
30779268 |
2020 |
|
Ataxia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic.
|
31738426 |
2019 |
|
Cerebellar Ataxia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic.
|
31738426 |
2019 |
|
Ulcerative Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
MTC-miR146b should be regarded as an effective candidate for oral delivery and could improve the efficacy of immunotherapies for ulcerative colitis and colitis-associated cancer.
|
30445446 |
2019 |
|
Dejerine-Sottas Disease (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Strikingly, MTC-miR146b mimic oral administration protected miR-146b-deficient mice from dextran sodium sulphate [DSS] injury and the colitis-associated cancer process.
|
30445446 |
2019 |
|
Dizziness
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic.
|
31738426 |
2019 |
|
fibroma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Further studies are warranted to determine whether hyperplastic gingivitis and gingival growths, such as cysts and fibromas, occur with unusual frequency in patients with MTC.
|
31423894 |
2019 |
|
Mixed Salivary Gland Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among other tumour types, pan-TRK immunoreactivity was observed in all (100%) pleomorphic adenomas (particularly myoepithelial cell-rich, myxoid areas), 15 (83%) polymorphous adenocarcinomas, and four (20%) low-grade mucoepidermoid carcinomas, all with predominantly membranous/cytoplasmic immunoreactivity; only six cases showed focal (<10%) nuclear staining.
|
30801752 |
2019 |
|
Paresthesia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic.
|
31738426 |
2019 |
|
Salivary Gland Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Acinic cell carcinomas are negative for pan-TRK, though membranous expression of TRK is common in other salivary gland neoplasms.
|
30801752 |
2019 |
|
Vertigo
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic.
|
31738426 |
2019 |
|
Acute leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRK fusions have also been identified at lower frequencies across a broad range of other pediatric cancers, including undifferentiated sarcomas, gliomas, papillary thyroid cancers, spitzoid neoplasms, inflammatory myofibroblastic tumors, and acute leukemias.
|
30592640 |
2019 |
|
Acinar Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Acinic cell carcinomas are negative for pan-TRK, though membranous expression of TRK is common in other salivary gland neoplasms.
|
30801752 |
2019 |
|
Mucoepidermoid Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among other tumour types, pan-TRK immunoreactivity was observed in all (100%) pleomorphic adenomas (particularly myoepithelial cell-rich, myxoid areas), 15 (83%) polymorphous adenocarcinomas, and four (20%) low-grade mucoepidermoid carcinomas, all with predominantly membranous/cytoplasmic immunoreactivity; only six cases showed focal (<10%) nuclear staining.
|
30801752 |
2019 |
|
Childhood Acute Myeloid Leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Moreover, TARP expression was significantly associated with a fms-like tyrosine kinase receptor-3 internal tandem duplications in pediatric acute myeloid leukemia.
|
31371409 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, intracranial activity has been observed with both agents in TRK fusion-positive solid tumours with brain metastases and primary brain tumours.
|
31738426 |
2019 |
|
Knee pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
To investigate the TrkA inhibitor, ASP7962, for treatment of painful knee osteoarthritis.
|
31356878 |
2019 |
|
Cerebellar Hypoplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Further, de novo gain-of-function variants in PDGFRB, a tyrosine kinase receptor essential for vascular progenitor signaling, were associated with CBLH, and this discovery links genetic and non-genetic etiologies.
|
31474318 |
2019 |
|
Hyperplastic gingivitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further studies are warranted to determine whether hyperplastic gingivitis and gingival growths, such as cysts and fibromas, occur with unusual frequency in patients with MTC.
|
31423894 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Afatinib is an irreversible tyrosine kinase receptor inhibitor which was approved lately by USFDA for the treatment of metastatic non-small cell lung cancer (NSCLC).
|
30640044 |
2019 |
|
Hematopoietic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
AXL, a tyrosine kinase receptor, is commonly overexpressed in several solid tumours and numerous hematopoietic malignancies including acute myeloid leukaemia, acute lymphocytic leukaemia, chronic myeloid leukaemia, chronic lymphocytic leukaemia and multiple myeloma.
|
31075180 |
2019 |